Guardant Health, Inc. (GH)

Market Cap	6.26B
Revenue (ttm)	774.00M
Net Income (ttm)	-416.55M
Shares Out	123.89M
EPS (ttm)	-3.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	956,903
Open	50.29
Previous Close	50.18
Day's Range	49.25 - 50.91
52-Week Range	20.14 - 53.42
Beta	1.45
Analysts	Strong Buy
Price Target	54.35 (+7.62%)
Earnings Date	Aug 6, 2025

About GH

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that p...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 4, 2018
• Employees: 2,021
• Stock Exchange: NASDAQ
• Ticker Symbol: GH
• Website: https://guardanthealth.com

Financial Performance

In 2024, Guardant Health's revenue was $739.02 million, an increase of 31.04% compared to the previous year's $563.95 million. Losses were -$436.37 million, -8.98% less than in 2023.

Analyst Summary

According to 20 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $54.35, which is an increase of 7.62% from the latest price.

Price Target

$54.35

(7.62% upside)

Analyst Consensus: Strong Buy